NOMAD Power Solutions, Inc.(NMAD)

Biotechnology · Boca Raton, FL

$4.30+0.29 (+7.10%)

Delayed quote: Oct 6, 2026, 2:22 PM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T18:27:42.909Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:27:42.909Z.

Quote observation: 2026-10-06T18:22:56.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 53,147,506
Total debt · period ending 2026-06-30: 1,101
Cash · period ending 2026-06-30: 12,670
TTM revenue · period ending 2026-06-30: 0

FMP input reference: f372f39edc86e990c580289f142e0fc1828f45467bffd466be8591b91f734aee

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NMAD EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

NMAD Competitors' EV/Sales Ratio

NMAD

NOMAD Power Solutions, Inc.

Current

Market Cap

$53.15M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DWTX

Dogwood Therapeutics, Inc.

vs NMAD

Market Cap

$52.46M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BTMD

biote Corp.

vs NMAD

Market Cap

$51.83M

EV/Sales Ratio

0.92x

TTM Avg

0.87x

3Y Avg

1.10x

5Y Avg

0.92x

ALDX

Aldeyra The

vs NMAD

Market Cap

$53.35M

EV/Sales Ratio

N/A

TTM Avg

3.74x

3Y Avg

3.42x

5Y Avg

3.42x

EXOZ

eXoZymes, Inc.

vs NMAD

Market Cap

$51.42M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RANI

Rani Therapeutics Holdings, Inc.

vs NMAD

Market Cap

$53.50M

EV/Sales Ratio

10.70x

TTM Avg

51.21x

3Y Avg

45.57x

5Y Avg

60.27x

TENX

Tenax Therapeutics, Inc.

vs NMAD

Market Cap

$51.19M

EV/Sales Ratio

N/A

TTM Avg

828.86x

3Y Avg

1129.78x

5Y Avg

739.58x

IMA

ImageneBio Inc

vs NMAD

Market Cap

$53.24M

EV/Sales Ratio

N/A

TTM Avg

46.89x

3Y Avg

17.85x

5Y Avg

13.82x

ELOX

Eloxx Pharmaceuticals, Inc.

vs NMAD

Market Cap

$50.86M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLNN

Clene Inc.

vs NMAD

Market Cap

$50.83M

EV/Sales Ratio

322.37x

TTM Avg

420.85x

3Y Avg

206.07x

5Y Avg

241.56x

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
NOMAD Power Solutions, Inc. (NMAD)	$53.15M	N/A	N/A	N/A	N/A
Dogwood Therapeutics, Inc. (DWTX)vs ›	$52.46M	N/A	N/A	N/A	N/A
biote Corp. (BTMD)vs ›	$51.83M	0.92x	0.87x	1.10x	0.92x
Aldeyra The (ALDX)vs ›	$53.35M	N/A	3.74x	3.42x	3.42x
eXoZymes, Inc. (EXOZ)vs ›	$51.42M	N/A	N/A	N/A	N/A
Rani Therapeutics Holdings, Inc. (RANI)vs ›	$53.50M	10.70x	51.21x	45.57x	60.27x
Tenax Therapeutics, Inc. (TENX)vs ›	$51.19M	N/A	828.86x	1129.78x	739.58x
ImageneBio Inc (IMA)vs ›	$53.24M	N/A	46.89x	17.85x	13.82x
Eloxx Pharmaceuticals, Inc. (ELOX)vs ›	$50.86M	N/A	N/A	N/A	N/A
Clene Inc. (CLNN)vs ›	$50.83M	322.37x	420.85x	206.07x	241.56x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics